TP-10 is a selective PDE10A inhibitor with an IC 50 value of 0.8 nM. TP-10 shows an antioxidant activity with IC 50 s of 31.72 and 16.04 μg/ml for DPPH and CUPRAC, respectively. TP-10 can be used for the research of neuropathy In Vitro TP-10 (10 μg /mL; 24 h) affects total reactive oxygen species in human brain-derived cells (U-87 MG). MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Viability AssayCell Line: U-87 MG cells Concentration: 10 μg/ml Incubation Time: 24 hours Result: Decreased the total number of ROS-positive cells and showed no toxic effects to U-87 MG cells. In Vivo TP-10 (0.1-10 mg/kg; i.h. once) shows an effect on cyclic nucleotides. MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: Male CD ratsDosage: 0.1, 0.32, 1.0, 3.2 and 10 mg/kg Administration: Subcutaneous injection; 0.1-10 mg/kg once Result: Dose- and time-dependently increased the levels of both cGMP and cAMP in striatal of mice. Increased pCREB-LI level first and returned to basal levels after injected for 3 hours at a dose of 3.2 mg/kg. Form:Solid IC50& Target:IC50: 0.8 nM (PDE10A), 31.72 μg/mL (DPPH), 16.04 μg/mL (CUPRAC)